Temozolomide + Nivolumab in MGMT Methylated Oesophagogastric Cancer

NCT04984733 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

13

Enrollment

OTHER

Sponsor class

Conditions

Adenocarcinoma - GEJ
Cancer of Esophagus

Interventions

DRUG: Temozolomide
DRUG: Temozolomide 50mg/m2/day
DRUG: Temozolomide 3 month
DRUG: Temozolomide 24month

Sponsor

University of Southampton

Collaborators

[object Object]